BD Diagnostics has received Food and Drug Administration approval for its FocalPoint imaging system that is designed to detect cervical cancer.

BD Diagnostics is the new name for TriPath Imaging. Becton Dickinson purchased the Burlington-based company in 2006.

The FocalPoint is the first in a series of new cancer diagnostics offerings being developed by BD Diagnostics, according to the company.

An estimated 4,000 women die every year from cervical cancer in the United States. The company believes its new technology will reduce the number of “false negatives” from Pap smears administered to women as a test for cancer.